RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors

Synthetic lethal targeting of homologous recombination (HR)–deficient ovarian cancers (OvCas) with poly(ADP-ribose) polymerase inhibitors (PARPis) has attracted considerable attention. Olaparib was the first PARPi approved by the Food and Drug Administration, offering significant clinical benefits i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peng, Lin, Chunxiu, Liu, Lanlan, Lu, Ziwen, Tu, Zhigang, Liu, Hanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463535/
https://www.ncbi.nlm.nih.gov/pubmed/35952757
http://dx.doi.org/10.1016/j.jbc.2022.102354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463535/
https://www.ncbi.nlm.nih.gov/pubmed/35952757
http://dx.doi.org/10.1016/j.jbc.2022.102354

Ejemplares similares